Poster Session 2P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2016 Published by Elsevier Inc.